Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:clinicalTrialPhase |
Phase 3 (Tinlarebant)
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focusesOn |
metabolic diseases
ophthalmic diseases |
| gptkbp:foundedYear |
2016
|
| gptkbp:founder |
Kun-Liang Guan
|
| gptkbp:headquartersLocation |
gptkb:San_Diego,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Belite Bio
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:leadProduct |
Tinlarebant (LBS-008)
|
| gptkbp:notableFor |
developing treatments for Stargardt disease
developing treatments for geographic atrophy |
| gptkbp:publiclyTraded |
true
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
BLTE
|
| gptkbp:website |
https://www.belitebio.com/
|
| gptkbp:bfsParent |
gptkb:Sorrento_Mesa
|
| gptkbp:bfsLayer |
8
|